HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Takeda Intelligence Report

Intelligence report

Intelligence Report · ~12 min read

Takeda Intelligence Report

Generated from 9 signals · 3 evidence sources

Type

Company Intelligence Report

Generated

Aug 4, 2026

Confidence

Moderate Confidence · 67%

Evidence

37 items

Sources

14

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Takeda maintains an active intelligence profile across Neurology, ADHD, Sleep Disorders, Oncology, CD30-positive Lymphoma. 9 signals are linked with 0 investigate-priority items requiring leadership attention. Competitive pressure is low with high portfolio impact. Evidence coverage stands at 67% across 3 tracked sources. Highest-priority development: FDA Accepts First In Silico Drug Development Tool Under ISTAND Program to Help Predict Drug-Induced Liver Injury. Regulatory precedent. Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Takeda; the same agency is already in play for this signal, so precedent weight is higher.

Key Developments

Material intelligence events ranked by strategic relevance.

  1. regulatory

    FDA Accepts First In Silico Drug Development Tool Under ISTAND Program to Help Predict Drug-Induced Liver Injury

    Regulatory precedent may inform portfolio positioning

    View detail
  2. regulatory

    FDA AP — VYVANSE (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  3. regulatory

    Notice: Register of authorised online sellers of medicines in Northern Ireland

    Regulatory precedent may inform portfolio positioning

    View detail
  4. regulatory

    FDA Accepts First In Silico Drug Development Tool Under ISTAND Program to Help Predict Drug-Induced Liver Injury

    Regulatory precedent may inform portfolio positioning

    View detail
  5. regulatory

    Form FDA 3674 - Certifications To Accompany Drug, Biological Product, and Device Applications/Submissions

    Regulatory precedent may inform portfolio positioning

    View detail
  6. regulatory

    IND Application Reporting: IND Safety Reports

    Regulatory precedent may inform portfolio positioning

    View detail
  7. regulatory

    Investigational New Drug (IND) Application

    Regulatory precedent may inform portfolio positioning

    View detail
  8. regulatory

    FDA AP — VYVANSE (SUPPL)

    Regulatory precedent may inform portfolio positioning

    View detail
  9. regulatory

    Innovative Science and Technology Approaches for New Drugs (ISTAND) Program Submission Process

    Regulatory precedent may inform portfolio positioning

    View detail
  10. regulatory

    ANDAs: Pre-Submission Facility Correspondence Related to Prioritized Generic Drug Submissions

    Regulatory precedent may inform portfolio positioning

    View detail
  11. regulatory

    eCTD Submission Standards for eCTD v3.2.2 and Regional M1

    Regulatory precedent may inform portfolio positioning

    View detail
  12. regulatory

    Clinical Outcome Assessments (COA) Qualification Program Submissions

    Regulatory precedent may inform portfolio positioning

    View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Opportunity score 392 with buyer quality 10 (Enterprise). Competitive pressure: Low. Portfolio impact: High.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

  • FDA Accepts First In Silico Drug Development Tool Under ISTAND Program to Help Predict Drug-Induced Liver Injury

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — VYVANSE (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Notice: Register of authorised online sellers of medicines in Northern Ireland

    Moderate Confidence · 72%

    Regulatory precedent may inform portfolio positioning

    Source: MHRA, MHRA, Regunera

    View evidence

  • FDA Accepts First In Silico Drug Development Tool Under ISTAND Program to Help Predict Drug-Induced Liver Injury

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Form FDA 3674 - Certifications To Accompany Drug, Biological Product, and Device Applications/Submissions

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • IND Application Reporting: IND Safety Reports

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Investigational New Drug (IND) Application

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA AP — VYVANSE (SUPPL)

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Innovative Science and Technology Approaches for New Drugs (ISTAND) Program Submission Process

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • ANDAs: Pre-Submission Facility Correspondence Related to Prioritized Generic Drug Submissions

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • eCTD Submission Standards for eCTD v3.2.2 and Regional M1

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Clinical Outcome Assessments (COA) Qualification Program Submissions

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • eCTD Submission Standards for eCTD v4.0 and Regional M1

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA Accepts First In Silico Drug Development Tool Under ISTAND Program to Help Predict Drug-Induced Liver Injury

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Notice: Register of authorised online sellers of medicines in Northern Ireland

    Moderate Confidence · 72%

    Regulatory precedent may inform portfolio positioning

    Source: MHRA, MHRA, Regunera

    View evidence

  • Medical Products for Rare Diseases and Conditions

    Moderate Confidence · 65%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

  • FDA Accepts Supplement for Vyvanse (NDA 208510) from Takeda

    Neurology · ADHD

  • FDA Accepts Supplement for MYDAYIS by Takeda

    Neurology · ADHD

  • Takeda's TAK-360 Trial for Narcolepsy Type 1 Underway

    Neurology · Sleep Disorders

  • Brentuximab Vedotin Study in CD30-positive Lymphoma Launched by Takeda

    Oncology · CD30-positive Lymphoma

  • Fruquintinib Study in Metastatic Colorectal Cancer Patients in Poland

    Oncology · Colorectal Cancer

  • FDA Accepts Supplemental Application for Vyvanse by Takeda

    Neurology · ADHD

  • FDA Submission Update for Adderall XR 10 by Takeda

    Neurology · ADHD

  • FDA Accepts Supplement Application for VYVANSE by Takeda

    Neurology · ADHD

PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.